Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200546557> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4200546557 abstract "Abstract ObjectiveThe treatment options for epidermal growth factor receptor ( EGFR )-mutated non-small-cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR-tyrosine kinase inhibitors (TKIs), stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), brain surgery (BS), and anti-angiogenesis therapy. As treatment options evolve, the redefinition of optimal treatment strategies for improving survival is crucial.Methods150 EGFR- mutant NSCLC patients with BMs who received first- or second-generation EGFR-TKIs as first-line treatment between January 2012 and October 2019 were included in this analysis.ResultsAfter multivariate analysis, patients with graded prognostic assessments for lung cancer based on molecular markers (Lung-mol GPA) ≥ 3 (Hazard ratio (HR): 0.538, 95% Confidence Interval (CI): 0.35-0.83); who received afatinib or erlotinib as first-line treatment (HR:0.521, 95%CI: 0.33-0.82); underwent SRS therapy (HR:0.531, 95%CI: 0.32-0.87); or were sequentially treated with osimertinib (HR:0.400, 95%CI: 0.23-0.71) were associated with improved overall survival (OS). Furthermore, SRS plus EGFR-TKI provided more OS benefits in patients with Lung-mol GPA ≥ 3 compared with EGFR-TKI alone in our patient cohort (44.9 vs. 26.7 months, p = 0.005). The OS among patients who received sequential osimertinib therapy was significantly longer than those without osimertinib treatment (43.5 vs. 24.3 months, p < 0.001), regardless of T790 mutation status (positive vs. negative/unknown: 40.4 vs. 54.6 months, p = 0.093).ConclusionsThe study demonstrated that EGFR- mutant NSCLC patients with BMs could be precisely treated with SRS according to Lung-mol GPA ≥ 3. Sequential osimertinib was associated with prolonged survival, regardless of T790M status." @default.
- W4200546557 created "2021-12-31" @default.
- W4200546557 creator A5010266809 @default.
- W4200546557 creator A5031839856 @default.
- W4200546557 creator A5034837211 @default.
- W4200546557 creator A5057125005 @default.
- W4200546557 creator A5060187418 @default.
- W4200546557 creator A5064231115 @default.
- W4200546557 creator A5074784103 @default.
- W4200546557 creator A5077913813 @default.
- W4200546557 date "2021-12-23" @default.
- W4200546557 modified "2023-10-14" @default.
- W4200546557 title "The Optimal Therapeutic Strategy for Patients with EGFR-Mutated Non–Small Cell Lung Cancer with Brain Metastasis: A Real-World Study from Taiwan" @default.
- W4200546557 doi "https://doi.org/10.21203/rs.3.rs-1183444/v1" @default.
- W4200546557 hasPublicationYear "2021" @default.
- W4200546557 type Work @default.
- W4200546557 citedByCount "0" @default.
- W4200546557 crossrefType "posted-content" @default.
- W4200546557 hasAuthorship W4200546557A5010266809 @default.
- W4200546557 hasAuthorship W4200546557A5031839856 @default.
- W4200546557 hasAuthorship W4200546557A5034837211 @default.
- W4200546557 hasAuthorship W4200546557A5057125005 @default.
- W4200546557 hasAuthorship W4200546557A5060187418 @default.
- W4200546557 hasAuthorship W4200546557A5064231115 @default.
- W4200546557 hasAuthorship W4200546557A5074784103 @default.
- W4200546557 hasAuthorship W4200546557A5077913813 @default.
- W4200546557 hasBestOaLocation W42005465571 @default.
- W4200546557 hasConcept C121608353 @default.
- W4200546557 hasConcept C126322002 @default.
- W4200546557 hasConcept C143998085 @default.
- W4200546557 hasConcept C207103383 @default.
- W4200546557 hasConcept C2776256026 @default.
- W4200546557 hasConcept C2777626846 @default.
- W4200546557 hasConcept C2778087573 @default.
- W4200546557 hasConcept C2778164965 @default.
- W4200546557 hasConcept C2779013556 @default.
- W4200546557 hasConcept C2779438470 @default.
- W4200546557 hasConcept C2780387249 @default.
- W4200546557 hasConcept C2780586478 @default.
- W4200546557 hasConcept C44249647 @default.
- W4200546557 hasConcept C509974204 @default.
- W4200546557 hasConcept C71924100 @default.
- W4200546557 hasConceptScore W4200546557C121608353 @default.
- W4200546557 hasConceptScore W4200546557C126322002 @default.
- W4200546557 hasConceptScore W4200546557C143998085 @default.
- W4200546557 hasConceptScore W4200546557C207103383 @default.
- W4200546557 hasConceptScore W4200546557C2776256026 @default.
- W4200546557 hasConceptScore W4200546557C2777626846 @default.
- W4200546557 hasConceptScore W4200546557C2778087573 @default.
- W4200546557 hasConceptScore W4200546557C2778164965 @default.
- W4200546557 hasConceptScore W4200546557C2779013556 @default.
- W4200546557 hasConceptScore W4200546557C2779438470 @default.
- W4200546557 hasConceptScore W4200546557C2780387249 @default.
- W4200546557 hasConceptScore W4200546557C2780586478 @default.
- W4200546557 hasConceptScore W4200546557C44249647 @default.
- W4200546557 hasConceptScore W4200546557C509974204 @default.
- W4200546557 hasConceptScore W4200546557C71924100 @default.
- W4200546557 hasLocation W42005465571 @default.
- W4200546557 hasOpenAccess W4200546557 @default.
- W4200546557 hasPrimaryLocation W42005465571 @default.
- W4200546557 hasRelatedWork W150263754 @default.
- W4200546557 hasRelatedWork W2810945895 @default.
- W4200546557 hasRelatedWork W2884036322 @default.
- W4200546557 hasRelatedWork W2888534976 @default.
- W4200546557 hasRelatedWork W3082721204 @default.
- W4200546557 hasRelatedWork W3090229303 @default.
- W4200546557 hasRelatedWork W4200546557 @default.
- W4200546557 hasRelatedWork W4225662054 @default.
- W4200546557 hasRelatedWork W4281690819 @default.
- W4200546557 hasRelatedWork W4284885728 @default.
- W4200546557 isParatext "false" @default.
- W4200546557 isRetracted "false" @default.
- W4200546557 workType "article" @default.